A 9-Month Open-Label Extension Study of the Long-Term Safety of DVS SR in Outpatients With Pain Associated With Diabetic Peripheral Neuropathy.
Phase of Trial: Phase III
Latest Information Update: 15 Jul 2010
At a glance
- Drugs Desvenlafaxine (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Wyeth
- 12 May 2010 Patient number amended from 240 to 237 as reported by ClinicalTrials.gov.
- 23 Jan 2010 New trial record